Cargando…

Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study

Growing evidence has highlighted that angiotensin-converting enzyme (ACE)-inhibitors (ACEi)/AT1 receptor blockers (ARBs) may influence the complex interplay between dopamine and the renin-angiotensin system in the nigrostriatal pathway, thus affecting the development of levodopa-induced dyskinesia i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Contaldi, Elena, Magistrelli, Luca, Milner, Anna V., Cosentino, Marco, Marino, Franca, Comi, Cristoforo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374578/ https://www.ncbi.nlm.nih.gov/pubmed/33907036 http://dx.doi.org/10.4103/1673-5374.313061

Ejemplares similares

Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson’s Disease
por: Contaldi, Elena, et al.
Publicado: (2021)

Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio Are Associated with Mild Cognitive Impairment in Parkinson’s Disease: A Single-Center Longitudinal Study
por: Contaldi, Elena, et al.
Publicado: (2022)

The PROB-PD trial: a pilot, randomised, placebo-controlled study protocol to evaluate the feasibility and potential efficacy of probiotics in modulating peripheral immunity in subjects with Parkinson’s disease
por: Martini, Stefano, et al.
Publicado: (2023)

Polymorphisms of Dopamine Receptor Genes and Parkinson’s Disease: Clinical Relevance and Future Perspectives
por: Magistrelli, Luca, et al.
Publicado: (2021)

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
por: Comi, Cristoforo, et al.
Publicado: (2017)

The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson’s Disease
por: Magistrelli, Luca, et al.
Publicado: (2021)

T Lymphocytes in Parkinson’s Disease
por: Contaldi, Elena, et al.
Publicado: (2022)

Motor and non-motor symptom improvement after mRNA-1273 vaccine in a Parkinson’s disease patient
por: Contaldi, Elena, et al.
Publicado: (2021)

Striatal dopamine transporter imaging in Parkinson’s disease drug-naïve patients: focus on sexual dysfunction
por: Contaldi, Elena, et al.
Publicado: (2022)

Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians
por: De Marchi, Fabiola, et al.
Publicado: (2021)

Immune Response Modifications in the Genetic Forms of Parkinson’s Disease: What Do We Know?
por: Magistrelli, Luca, et al.
Publicado: (2022)

The Effects of COVID-19-Related Restrictions on Parkinson’s Disease Patients in Italy: Results of a Structured Survey
por: Martini, Stefano, et al.
Publicado: (2022)

LOW DOSE LEVODOPA IN TARDIVE DYSKINESIA
por: Sethi, Sujata, et al.
Publicado: (1990)

Involvement of Autophagy in Levodopa‐Induced Dyskinesia
por: Feyder, Michael, et al.
Publicado: (2021)

Clinical Aspects and Management of Levodopa-Induced Dyskinesia
por: Tambasco, Nicola, et al.
Publicado: (2012)

“Cueing” for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Schaeffer, Eva, et al.
Publicado: (2016)

Resveratrol Alleviates Levodopa-Induced Dyskinesia in Rats
por: Zheng, Chang-Qing, et al.
Publicado: (2021)

Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
por: Bargiotas, Panagiotis, et al.
Publicado: (2013)

Future Scenarios for Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Cerasa, Antonio, et al.
Publicado: (2015)

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
por: Krishnan, Syam, et al.
Publicado: (2017)

Cerebellar connectivity in Parkinson's disease with levodopa‐induced dyskinesia
por: Yoo, Han Soo, et al.
Publicado: (2019)

Levodopa-induced belly dancer's dyskinesia: Case report
por: Cavalcante-Filho, José Renan Miranda, et al.
Publicado: (2020)

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
por: Yang, Xinxin, et al.
Publicado: (2012)

Basal Ganglia Circuits Underlying the Pathophysiology of Levodopa-Induced Dyskinesia
por: Barroso-Chinea, Pedro, et al.
Publicado: (2010)

The acute brain response to levodopa heralds dyskinesias in Parkinson disease
por: Herz, Damian M., et al.
Publicado: (2014)

Cerebellum in Levodopa-Induced Dyskinesias: The Unusual Suspect in the Motor Network
por: Kishore, Asha, et al.
Publicado: (2014)

Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management
por: Pandey, Sanjay, et al.
Publicado: (2017)

Recent Advances in the Development of Experimental Therapeutics for Levodopa-Induced Dyskinesia
por: Martini, Michael L., et al.
Publicado: (2019)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease
por: Martinez-Carrasco, Alejandro, et al.
Publicado: (2023)

Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients
por: Kustrimovic, Natasa, et al.
Publicado: (2018)

Compound Formula Rehmannia alleviates levodopa-induced dyskinesia in Parkinson's disease
por: Teng, Long, et al.
Publicado: (2014)

Clinical Features, Pathophysiology, and Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
por: Guridi, J., et al.
Publicado: (2012)

Resting‐state connectivity predicts levodopa‐induced dyskinesias in Parkinson's disease
por: Herz, Damian M., et al.
Publicado: (2016)

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson’s Disease
por: Pagano, Gennaro, et al.
Publicado: (2017)

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation
por: Li, Michael H., et al.
Publicado: (2018)

Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
por: Gan, Caiting, et al.
Publicado: (2020)

White matter hyperintensities and risk of levodopa‐induced dyskinesia in Parkinson’s disease
por: Chung, Seok Jong, et al.
Publicado: (2020)

Nigral Iron Deposition Is Associated With Levodopa-Induced Dyskinesia in Parkinson’s Disease
por: Song, Tianbin, et al.
Publicado: (2021)

Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
por: König, Eva, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hlp04j9grq5fme6vl5cppsb2v2